Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review

BACKGROUND: Pegylated liposomal doxorubicin plays an important role in the treatment of patients with severe refractory human immunodeficiency virus (HIV)-associated Kaposi sarcoma (KS). High cumulative doses of conventional doxorubicin exceeding 500 mg/m(2) are known to cause cardiac toxicity. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishihara, Ayaka, Hatakeyama, Shuji, Suzuki, Jun, Amano, Yusuke, Sasahara, Teppei, Toshima, Masaki, Morisawa, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794836/
https://www.ncbi.nlm.nih.gov/pubmed/31615436
http://dx.doi.org/10.1186/s12879-019-4500-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794836/
https://www.ncbi.nlm.nih.gov/pubmed/31615436
http://dx.doi.org/10.1186/s12879-019-4500-7

Ejemplares similares